Substandard/counterfeit antimicrobial drugs

Clinical Microbiology Reviews

Volumn 28, Issue 2, 2015, Pages 443-464

  Kelesidis, Theodoros ^a   Falagas, Matthew E ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; BENZATHINE PENICILLIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; COUNTERFEIT DRUG; ERYTHROMYCIN; FOLIC ACID ANTAGONIST; IMIDAZOLE; ISONIAZID PLUS RIFAMPICIN; KETOCONAZOLE; MACROLIDE; METRONIDAZOLE; OSELTAMIVIR; OXYTETRACYCLINE PLUS POLYMYXIN B; PYRIMETHAMINE PLUS SULFADOXINE; QUINOLONE DERIVATIVE; RIFAMYCIN; TETRACYCLINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VIRUS VACCINE;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; EOSINOPHILIA MYALGIA SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; MORBIDITY; MORTALITY; PUBLIC HEALTH; QUALITY CONTROL; RADIOFREQUENCY IDENTIFICATION; ULTRAVIOLET SPECTROPHOTOMETRY; WORLD HEALTH ORGANIZATION; CHEMISTRY; INTERNATIONAL COOPERATION; STANDARDS; SUPPLY AND DISTRIBUTION;

ANTI-INFECTIVE AGENTS; COUNTERFEIT DRUGS; INTERNATIONAL COOPERATION; PUBLIC HEALTH;

EID: 84926041400     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00072-14     Document Type: Article

References (235)

1. WHO. 1999. Counterfeit and sub-standard drugs in Myanmar and Vietnam. WHO, Geneva, Switzerland.
2. Shakoor O, Taylor RB, Behrens RH. 1997. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 2:839-845. http://dx.doi.org/10.1046/j.1365-3156.1997.d01-403.x.
3. Pecoul B, Chirac P, Trouiller P, Pinel J. 1999. Access to essential drugs in poor countries: a lost battle? JAMA 281:361-367. http://dx.doi.org/10 .1001/jama.281.4.361.
4. Menkes DB. 1997. Hazardous drugs in developing countries. BMJ 315: 1557-1558. http://dx.doi.org/10.1136/bmj.315.7122.1557.
5. Roy J. 1994. The menace of substandard drugs. World Health Forum 15:406-407.
6. Hanif M, Mobarak MR, Ronan A, Rahman D, Donovan JJ, Jr., Bennish ML. 1995. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. BMJ 311:88-91. http://dx .doi.org/10.1136/bmj.311.6997.88.
7. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J, Reid RG, Kolawole JA. 2001. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357:1933-1936. http://dx.doi .org/10.1016/S0140-6736(00)05065-0.
8. Wan Po AL. 2001. Too much, too little, or none at all: dealing with substandard and fake drugs. Lancet 357:1904. http://dx.doi.org/10.1016 /S0140-6736(00)05092-3.
9. Newton P, Proux S, Green M, Smithuis F, Rozendaal J, Prakongpan S, Chotivanich K, Mayxay M, Looareesuwan S, Farrar J, Nosten F, White NJ. 2001. Fake artesunate in southeast Asia. Lancet 357:1948-1950. http: //dx.doi.org/10.1016/S0140-6736(00)05085-6.
10. Wondemagegnehu E. 1995. Counterfeit and substandard drugs in Myanmar and Vietnam. WHO/EDM/QSM/99.3. WHO, Geneva, Switzerland.
11. Frankish H. 2003.WHOsteps up campaign on counterfeit drugs. Lancet 362:1730. http://dx.doi.org/10.1016/S0140-6736(03)14891-X.
12. World Health Organization. 1999. Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs. WHO, Geneva, Switzerland.
13. Pincock S. 2003. WHO tries to tackle problem of counterfeit medicines in Asia. BMJ 327:1126. http://dx.doi.org/10.1136/bmj.327.7424.1126.
14. Ahmad K. 2004. Antidepressants are sold as antiretrovirals inDRCongo. Lancet 363:713. http://dx.doi.org/10.1016/S0140-6736(04)15670-5.
15. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. 2007. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 60:214-236. http://dx.doi.org/10.1093/jac/dkm109.
16. Newton PN, Green MD, Fernandez FM, Day NP, White NJ. 2006. Counterfeit anti-infective drugs. Lancet Infect Dis 6:602-613. http://dx .doi.org/10.1016/S1473-3099(06)70581-3.
17. Delepierre A, Gayot A, Carpentier A. 2012. Update on counterfeit antibiotics worldwide; public health risks. Med Mal Infect 42:247-255. http://dx.doi.org/10.1016/j.medmal.2012.04.007.
18. Attaran A, Barry D, Basheer S, Bate R, Benton D, Chauvin J, Garrett L, Kickbusch I, Kohler JC, Midha K, Newton PN, Nishtar S, Orhii P, McKee M. 2012. How to achieve international action on falsified and substandard medicines. BMJ 345:e7381. http://dx.doi.org/10.1136/bmj .e7381.
19. Videau JV, Fundafunda B. 2000. Generic drugs: the hidden issues of quality and cost.WHOdrug information, p 77-81.WHO,Geneva, Switzerland.
20. World Health Organization. 1997. Quality assurance of pharmaceuticals, vol 1. World Health Organization, Geneva, Switzerland.
21. World Health Organization. 1999. Quality assurance of pharmaceuticals, vol 2. World Health Organization, Geneva, Switzerland.
22. World Health Organization. 2014. What encourages counterfeiting of drugs? http://www.who.int/medicines/services/counterfeit/faqs/15/en/. Accessed 16 January 2014.
23. World Health Organization. 2014. What are substandard medicines? http://www.who.int/medicines/services/counterfeit/faqs/06/en/. Accessed 26 January 2014.
24. Stenson B, Lindgren BH, Synhakhang L, Tomson G. 1998. The quality of drugs in private pharmacies in the Lao People's Democratic Republic. Int J Risk Safety Med 11:243-249.
25. Masland T, Marshall R. 1990. "A really nasty business." Fake pharmaceuticals look like the real thing but they can be lethal. Newsweek, 5 November 1990.
26. Moken MC. 2003. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices. Am J Law Med 29:525-542.
27. Reidenberg MM, Conner BA. 2001. Counterfeit and substandard drugs. Clin Pharmacol Ther 69:189-193. http://dx.doi.org/10.1067/mcp.2001 .114672.
28. Syhakhang L, Lundborg CS, Lindgren B, Tomson G. 2004. The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999. Pharm World Sci 26:333-338. http://dx.doi.org/10.1007/s11096 -004-0558-3.
29. Hogerzeil HV, de Goeje MJ, Abu-Reid IO. 1991. Stability of essential drugs in Sudan. Lancet 338:754-755. http://dx.doi.org/10.1016/0140 -6736(91)91470-F.
30. Ballereau F, Prazuck T, Schrive I, Lafleuriel MT, Rozec D, Fisch A, Lafaix C. 1997. Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. Am J Trop Med Hyg 57:31-36.
31. Risha PG, Shewiyo D, Msami A, Masuki G, Vergote G, Vervaet C, Remon JP. 2002. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop Med Int Health 7:701-707. http://dx.doi .org/10.1046/j.1365-3156.2002.00937.x.
32. Murthy KS, Ghebre-Sellassie I. 1993. Current perspectives on the dissolution stability of solid oral dosage forms. J Pharm Sci 82:113-126. http://dx.doi.org/10.1002/jps.2600820202.
33. Pandit JK, Tripathi MK, Babu RJ. 1997. Effect of tablet disintegrants on the dissolution stability of nalidixic acid tablets. Pharmazie 52:538-540.
34. Rimoy GH, Moshi MJ, Massele AY. 2002. Comparative bioavailability of oral sugar-coated and plain formulation of chloroquine phosphate marketed in Tanzania. Trop Doct 32:15-17.
35. Nazerali H, Hogerzeil HV. 1998. The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study. BMJ 317:512-513. http://dx.doi.org/10.1136/bmj.317.7157.512.
36. Saville DJ. 2001. Influence of storage on in-vitro release of ibuprofen from sugar coated tablets. Int J Pharm 224:39-49. http://dx.doi.org/10 .1016/S0378-5173(01)00734-7.
37. Okeke IN, Lamikanra A. 1995. Quality and bioavailability of tetracycline capsules in a Nigerian semi-urban community. Int J Antimicrob Agents 5:250.
38. Kayumba PC, Risha PG, Shewiyo D, Msami A, Masuki G, Ameye D, Vergote G, Ntawukuliryayo JD, Remon JP, Vervaet C. 2004. The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. J Clin Pharm Ther 29:331-338. http://dx.doi.org/10 .1111/j.1365-2710.2004.00568.x.
39. Barbereau S. 2006. Guinea: fake medicines. E-Med 2006:January 12.
40. Lon CT, Tsuyuoka R, Phanouvong S, Nivanna N, Socheat D, Sokhan C, Blum N, Christophel EM, Smine A. 2006. Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg 100: 1019-1024. http://dx.doi.org/10.1016/j.trstmh.2006.01.003.
41. Kibwage IO, Ngugi JK. 2000. Sulphadoxine/pyrimethamine tablet products on the Kenyan market: quality concerns. East Central Afr J Pharm Sci 3:14-19.
42. World Health Organization. 2003. The quality of antimalarials. A study in selected African countries. World Health Organization, Geneva, Switzerland.
43. Amin AA, Snow RW, Kokwaro GO. 2005. The quality of sulphadoxinepyrimethamine and amodiaquine products in the Kenyan retail sector. J Clin Pharm Ther 30:559-565. http://dx.doi.org/10.1111/j.1365-2710 .2005.00685.x.
44. ten Ham M. 1992. Counterfeit drugs: implications for health. Adverse Drug React Toxicol Rev 11:59-65.
45. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJ, Talisuna AO, Proux S, Christophel EM, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NP, Greenwood BM, Nosten F, White NJ. 2006. Manslaughter by fake artesunate in Asia-will Africa be next? PLoS Med 3:e197. http://dx.doi.org/10.1371/journal.pmed.0030197.
46. Silverman M, Lydecker M, Lee PR. 1990. The drug swindlers. Int J Health Serv 20:561-572. http://dx.doi.org/10.2190/P32D-0141-M86B-F7AT.
47. Goodman PS. 2002. China's killer headache: fake pharmaceuticals. Washington Post, 30 August 2002.
48. Rozendaal J. 2001. Fake antimalaria drugs in Cambodia. Lancet 357:890. http://dx.doi.org/10.1016/S0140-6736(05)71830-4.
49. World Health Organization. 1999. Counterfeit drugs guidelines for the development of measures to combat counterfeit drugs. WHO, Geneva, Switzerland.
50. Legris C. 2005. Detection of counterfeit drugs by investigating their authenticity. Pilot study on the illicit drug market in Côte d'Ivoire. Thesis. University of Nancy, Nancy, France. http://www.remed.org/html /theses.html. Accessed 16 January 2014.
51. Prazuck T, Falconi I, Morineau G, Bricard-Pacaud V, Lecomte A, Ballereau F. 2002. Quality control of antibiotics before the implementation of an STD program in northern Myanmar. Sex Transm Dis 29: 624-627. http://dx.doi.org/10.1097/00007435-200211000-00002.
52. Smine A, Phanouvong S, Chanthap L, Tsuyuoka R, Nivanna N, Blum N. 2014. Antimalarial drug quality in Mekong countries. http://www .uspdqi.org/pubs/other/AntimalarialPoster.pdf. Accessed 16 January 2014.
53. Anonymous. 2005. Fake anti malaria drugs in Cambodia: a danger to public health. Final Report, NCM-Cambodia, USP, WHO. National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.
54. Center for Combating Counterfeit Drugs. 2014. The situation of counterfeit drugs. www.fda.moph.go.th/fda-net/html/product/drug/eng/zone _counterfeit/fak001.asp. Accessed 16 January 2014.
55. Sesay M. 1988. Fake drugs-a new threat of health care delivery. Africa Health June/July 1988:13-15.
56. Harper J. 2006. Counterfeit medicines survey report, Council for Europe. Council of Europe Publishing, Strasbourg, France.
57. Basco LK. 2004. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 70:245-250.
58. Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S, Petit A, Lynam AJ, Johnson A, Hien TT, McGready R, Farrar JJ, Looareesuwan S, Day NP, Green MD, White NJ. 2004. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 9:1241-1246. http://dx.doi.org/10.1111/j .1365-3156.2004.01342.x.
59. Almuzaini T, Choonara I, Sammons H. 2013. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 3:e002923. http://dx.doi.org/10.1136/bmjopen-2013-002923.
60. Gaudiano MC, Antoniella E, Bertocchi P, Valvo L. 2010. Development and validation of a reversed-phase LC method for analysing potentially counterfeit antimalarial medicines. J Pharm Biomed Anal 53:158-164. http://dx.doi.org/10.1016/j.jpba.2010.04.007.
61. World Health Organization. 2014. http://www.who.int/medicines /areas/quality_safety/quality_assurance/QualityAssurancePharmVol2 .pdf?ua_1. Accessed 16 January 2014.
62. Kenyon TA, Kenyon AS, Kgarebe BV, Mothibedi D, Binkin NJ, Layloff TP. 1999. Detection of substandard fixed-dose combination tuberculosis drugs using thin-layer chromatography. Int J Tuberc Lung Dis 3:S347- S350.
63. Petralanda I. 1995. Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region. Lancet 345:1433. http://dx.doi.org /10.1016/S0140-6736(95)92620-8.
64. Gibson L. 2004. Drug regulators study global treaty to tackle counterfeit drugs. BMJ 328:486. http://dx.doi.org/10.1136/bmj.328.7438.486.
65. World Health Organization. 1999. Summary of WHO counterfeit drug database as of April 1999, unpublished paper of the WHO Division of Drug Management and Policies. WHO, Geneva, Switzerland.
66. World Health Organization. 2000. World Health Organisation counterfeit drug reports: 1999-October 2000. www.who.int/medicines /services/counterfeit/overview/en/1. Accessed 16 January 2014.
67. Anonymous. 2002. Counterfeit drugs: threat to public health. Global Forum on Pharmaceutical Anticounterfeiting, Geneva, Switzerland, 22 to 25 September 2002.
68. Chakravarty S, Unnithan S, Ram A. 2001. Deadly doses. India Today, 29 January 2001, p 58-61.
69. Olori T. 1996. Nigeria-Health: bogus drugs-a national headache. Inter Press Service, 5 December 1996.
70. Fackler M. 2002. China's fake drugs kill thousands. San Francisco Examiner, 29 July 2002.
71. Rudolf PM, Bernstein IB. 2004. Counterfeit drugs. N Engl J Med 350: 1384-1386. http://dx.doi.org/10.1056/NEJMp038231.
72. Pharmaceutical Security Institute. 2014. Counterfeit situation. http: //www.psi-inc.org/incidentTrends.cfm. Accessed 24 January 2014.
73. Institute of Medicine. 2013. Countering the problem of falsified and substandard drugs. http://www.iom.edu/Reports/2013/Countering-the -Problem-of-Falsified-and-Substandard-Drugsaspx. Accessed 24 January 2014.
74. World Health Organization. 2012. Substandard/spurious/falselylabelled/ falsified/counterfeit medical products: report of the Working Group of Member States. http://apps.who.int/gb/ebwha/pdf_files/WHA 65/A65_23-en.pdf. Accessed 24 January 2014.
75. United Nations Office on Drugs and Crime. 2010. The globalization of crime. A transnational organized crime threat assessment. Counterfeit products 2010, p 183-189. https://www.unodc.org/documents/data-and -analysis/tocta/TOCTA_Report_2010_low_res.pdf. Accessed 24 January 2014.
76. United Nations Interregional Crime and Justice Research Institute. 14 December 2007. Counterfeiting. A global spread, a global threat. 4. The counterfeiting medicines, p 29, 63-72. http://www.unicri.it/news/article /0712-3_counterfeiting_crt_foundation. Accessed 23 January 2014.
77. Behrens RH, Awad AI, Taylor RB. 2002. Substandard and counterfeit drugs in developing countries. Trop Doct 32:1-2.
78. Kron MA. 1996. Substandard primaquine phosphate for US Peace Corps personnel. Lancet 348:1453-1454. http://dx.doi.org/10.1016/S0140 -6736(04)70100-2.
79. Giminez F, Bruneton C, Narong Rith DY. 1997. Etude de la qualite des medicaments vendus et dispenses au Cambodge. Med Mal Infect 271: 541-544.
80. Pole D, Ransome-Kuti O, Institute for Medical Informatics. 1989. Drug distribution & fake drugs in Nigeria: international workshop: proceedings of the workshop held on 12 April, Lagos, Nigeria. Institute for Medical Informatics, Basel Switzerland.
81. Kaur H, Goodman C, Thompson E, Thompson KA, Masanja I, Kachur SP, Abdulla S. 2008. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS One 3:e3403. http://dx.doi.org /10.1371/journal.pone.0003403.
82. Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, Okoye V, Okonkwo P. 2009. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J 8:22. http://dx.doi.org/10.1186/1475-2875-8-22.
83. Arya SC. 1995. Inadvertent supply of substandard drugs. World Health Forum 16:269.
84. Saywell T, McManus J. 2002. What's in that pill? Far Eastern Economic Review, 21 February 2002, p 34-40.
85. Primo-Carpenter J. 2004. A review of drug quality in Asia with focus on anti-infectives. Global initiative for quality medicines and their appropriate use. Drug Quality and Information Program, U.S. Pharmacopeia, Rockville, MD.
86. Chattopadhyay S. 1999. Access to essential drugs in poor countries. JAMA 282:631.
87. Maponga C, Ondari C. 2003. The quality of antimalarials. A study in selected African countries. WHO/EDM/PAR/2003.4. World Health Organization, Geneva, Switzerland. http://apps.who.int/medicinedocs/pdf /s4901e/s4901e.pdf. Accessed 24 January 2014.
88. Sabartova J, Toumi A, Ondari C. 2011. Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa. WHO/EMP/QSM/2011.1. World Health Organization, Geneva, Switzerland. http://www.who.int/medicines/publications/WHO_QAMSA_report .pdf. Accessed 24 January 2014.
89. Anonymous. 2009. A collaborative study by the WHO and DQI Survey of the quality of selected antimalarial medicines circulating in Madagascar, Senegal, and Uganda. http://apps.who.int/medicinedocs/documents /s17069e/s17069e.pdf. Accessed 24 January 2014.
90. Abdoulaye I, Chastanier H, Azondekon A, Dansou A, Bruneton C. 2006. Survey on the illicit drug market in Cotonou, Benin in March 2003. Med Trop (Mars) 66:573-576.
91. Newton PN, Dondorp A, Green M, Mayxay M, White NJ. 2003. Counterfeit artesunate antimalarials in southeast Asia. Lancet 362:169 http://dx.doi.org/10.1016/S0140-6736(03)13872-X.
92. Green MD. 2006. Antimalarial drug resistance and the importance of drug quality monitoring. J Postgrad Med 52:288-290.
93. Green MD, Nettey H, Wirtz RA. 2008. Determination of oseltamivir quality by colorimetric and liquid chromatographic methods. Emerg Infect Dis 14:552-556. http://dx.doi.org/10.3201/eid1404.061199.
94. Green MD, Mount DL, Wirtz RA, White NJ. 2000. A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate. J Pharm Biomed Anal 24:65-70. http://dx.doi.org/10.1016/S0731 -7085(00)00360-5.
95. Weaver AA, Reiser H, Barstis T, Benvenuti M, Ghosh D, Hunckler M, Joy B, Koenig L, Raddell K, Lieberman M. 2013. Paper analytical devices for fast field screening of beta lactam antibiotics and antituberculosis pharmaceuticals. Anal Chem 85:6453-6460. http://dx.doi.org/10 .1021/ac400989p.
96. Kibwage IO, Thuranira J, Migosi D. 1991. Quality performance of metronidazole tablet products on the Kenyan market. East Afr Med J 68:365-371.
97. Risha PG, Msuya Z, Clark M, Johnson K, Ndomondo-Sigonda M, Layloff T. 2008. The use of Minilabs to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience. Health Policy 87:217-222. http://dx.doi.org/10.1016/j.healthpol .2007.12.010.
98. Jahnke RW, Kusters G. 2001. Low-cost quality assurance of medicines using the GPHF-Minilab. Drug Information J 35:941-945.
99. Ida H, Kawai J. 2005. Analysis of wrapped or cased object by a hand-held X-ray fluorescence spectrometer. Forensic Sci Int 151:267-272. http://dx .doi.org/10.1016/j.forsciint.2005.02.017.
100. Ricci C, Nyadong L, Yang F, Fernandez FM, Brown CD, Newton PN, Kazarian SG. 2008. Assessment of hand-held Raman instrumentation for in situ screening for potentially counterfeit artesunate antimalarial tablets by FT-Raman spectroscopy and direct ionization mass spectrometry. Anal Chim Acta 623:178-186. http://dx.doi.org/10.1016/j.aca.2008 .06.007.
101. Phillips G. 2003. World Congress of Pharmacy and Pharmaceutical Sciences: anticounterfeiting measures. Pharm J 271:465. doi.org/10.1016/ S1473-3099(06)70581-3.
102. Iqbal M, Hakimm S, Hussain A, Mirza Z, Qureshi F, Abdulla E. 2004. Ofloxacin: laboratory evaluation of the antibacterial activity of 34 brands representing 31 manufacturers available in Pakistan. Pak J Med Sci 20: 349-356.
103. Takats Z, Wiseman JM, Gologan B, Cooks RG. 2004. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science 306:471-473. http://dx.doi.org/10.1126/science.1104404.
104. Cody RB, Laramee JA, Durst HD. 2005. Versatile new ion source for the analysis of materials in open air under ambient conditions. Anal Chem 77:2297-2302. http://dx.doi.org/10.1021/ac050162j.
105. Mulligan KJ, Brueggemeyer TW, Crockett DF, Schepman JB. 1996. Analysis of organic volatile impurities as a forensic tool for the examination of bulk pharmaceuticals. J Chromatogr B Biomed Appl 686:85-95. http://dx.doi.org/10.1016/S0378-4347(96)00109-0.
106. Peng SX, Borah B, Dobson RL, Liu YD, Pikul S. 1999. Application of LC-NMR and LC-MS to the identification of degradation products of a protease inhibitor in dosage formulations. J Pharm Biomed Anal 20:75-89. http://dx.doi.org/10.1016/S0731-7085(98)00311-2.
107. Newton PN, Lee SJ, Goodman C, Fernandez FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJ, Kokwaro GO, Lindegardh N, Lukulay P, White LJ, Day NP, Green MD, White NJ. 2009. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med 6:e52. http://dx.doi.org/10.1371/journal.pmed.1000052.
108. Scafi SH, Pasquini C. 2001. Identification of counterfeit drugs using near-infrared spectroscopy. Analyst 126:2218-2224. http://dx.doi.org /10.1039/b106744n.
109. Maurin JK, Plucinski F, Mazurek AP, Fijalek Z. 2007. The usefulness of simple X-ray powder diffraction analysis for counterfeit control-the Viagra((R)) example. J Pharm Biomed Anal 43:1514-1518. http://dx.doi .org/10.1016/j.jpba.2006.10.033.
110. Bate R, Jensen P, Hess K, Mooney L, Milligan J. 2013. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis 17:308-311. http://dx.doi.org/10.5588/ijtld.12.0355.
111. Baratta F, Germano A, Brusa P. 2012. Diffusion of counterfeit drugs in developing countries and stability of galenics stored for months under different conditions of temperature and relative humidity. Croat Med J 53:173-184. http://dx.doi.org/10.3325/cmj.2012.53.173.
112. Sabartova J, Nathanson E, Polishchuk O. 2011. Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union. WHO/EMP/QSM/2011.2. World Health Organization, Geneva, Switzerland. http://apps.who.int/medicinedocs /documents/s19053en/s19053en.pdf. Accessed 24 January 2014.
113. Seear M, Gandhi D, Carr R, Dayal A, Raghavan D, Sharma N. 2011. The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India. J Clin Pharm Ther 36:488-495. http://dx.doi.org/10.1111/j.1365-2710 .2010.01198.x.
114. Hadi U, van den Broek P, Kolopaking EP, Zairina N, Gardjito W, Gyssens IC. 2010. Cross-sectional study of availability and pharmaceutical quality of antibiotics requested with or without prescription (over the counter) in Surabaya, Indonesia. BMC Infect Dis 10:203. http://dx .doi.org/10.1186/1471-2334-10-203.
115. Zaheer M, Rahman S, Mahmood S, Saleem M. 2009. In vitro analysis and data comparison of market brands of ciprofloxacin, ofloxacin and levofloxacin. Pak J Sci Ind Res 52:186-190.
116. Obaid A. 2009. Quality of ceftriaxone in Pakistan: reality and resonance. Pak J Pharm Sci 22:220-229.
117. Bate R, Tren R, Mooney L, Hess K, Mitra B, Debroy B, Attaran A. 2009. Pilot study of essential drug quality in two major cities in India. PLoS One 4:e6003. http://dx.doi.org/10.1371/journal.pone.0006003.
118. Kyriacos S, Mroueh M, Chahine RP, Khouzam O. 2008. Quality of amoxicillin formulations in some Arab countries. J Clin Pharm Ther 33:375-379. http://dx.doi.org/10.1111/j.1365-2710.2008.00926.x.
119. Hu CQ, Zou WB, Hu WS, Ma XK, Yang MZ, Zhou SL, Sheng JF, Li Y, Cheng SH, Xue J. 2006. Establishment of a fast chemical identification system for screening of counterfeit drugs of macrolide antibiotics. J Pharm Biomed Anal 40:68-74. http://dx.doi.org/10.1016/j.jpba.2005.06 .026.
120. Okeke IN, Lamikanra A. 2001. Quality and bioavailability of ampicillin capsules dispensed in a Nigerian semi-urban community. Afr J Med Med Sci 30:47-51.
121. Laserson KF, Kenyon AS, Kenyon TA, Layloff T, Binkin NJ. 2001. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 5:448-454.
122. Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G. 1999. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 3:S309-S316.
123. Taylor RB, Shakoor O, Behrens RH. 1995. Drug quality, a contributor to drug resistance? Lancet 346:122. http://dx.doi.org/10.1016/S0140 -6736(95)92145-1.
124. Iwuagwu MA, Onyeonwu N. 1992. In vitro assessment of ampicillin capsules marketed in Nigeria. Int J Pharm Pract 1:167-171. http://dx.doi .org/10.1111/j.2042-7174.1992.tb00561.x.
125. Santosh KK, Raghuram TC, Krishnaswamy K. 1992. Bioavailability of different brands of tetracycline in undernourished subjects. Int J Clin Pharmacol Ther Toxicol 30:13-17.
126. Anonymous. 2014. Counterfeit Tamiflu. http://www.roche.com/identifying _counterfeit_product.pdf. Accessed January 16 2014.
127. Lindegardh N, Hien TT, Farrar J, Singhasivanon P, White NJ, Day NP. 2006. A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu((R)). J Pharm Biomed Anal 42:430-433. http://dx.doi.org/10.1016/j.jpba.2006.04.028.
128. World Health Organization. 2014. Medicines: spurious/falsely-labelled/ falsified/counterfeit (SFFC) medicines. http://www.who.int/mediacentre /factsheets/fs275/en/. Accessed 16 January 2014.
129. Food and Drug Administration. 2006. Cracking down on health fraud. http://www.fda.gov/drugs/emergencypreparedness/bioterrorismanddr ugpreparedness/ucm137261.htm. Accessed 16 January 2014.
130. Parfitt T. 2006. Russia cracks down on counterfeit drugs. Lancet 368: 1481-1482. http://dx.doi.org/10.1016/S0140-6736(06)69619-0.
131. Phanouvong S, Reiss S, Smine A. 2005. Why be concerned about the quality of antimalarial and ARV drugs?, poster. 7th Int Congr AIDS Asia Pacific, Kobe, Japan, 1 to 5 July 2005.
132. Anonymous. 2003. Drug access. Ethiopian health officials warn public against counterfeit antiretroviral drug. http://www.kaiserhealthnews.org /daily-reports/2003/october/09/dr00020261.aspx?referrer_search. Accessed 16 January 2014.
133. Anonymous. 2003. Black market bogus AIDS drugs. Addis Tribune, 10 October 2003. http://allafrica.com/stories/200310100530.html. Accessed 16 January 2014.
134. Anonymous. 2004. AAGM: AIDS drugs selling in city streets. The Nation (Kenya), 22 January 2004. http://www.nation.co.ke/. Accessed 16 January 2014.
135. Taylor P. 2012. Tanzanian drugmaker asserts innocence in fake ARV case. http://www.securingindustry.com/pharmaceuticals/tanzanian -drugmaker-asserts-innocence-in-fake-arv-case/s40/a1457/. Accessed 16 January 2014.
136. McLaughlin K. 2013. Fake drugs flood East African markets. http://ww w.washingtonpost.com/world/africa/fake-drugs-flood-east-african-mar kets/2013/01/23/a430289c-5f6e-11e2-9940-6fc488f3fecd_story.html. Accessed January 2014.
137. Anonymous. 2007. Zimbabwe: fake ART flood country. Financial Gazette, 26 July 2007. http://allafrica.com/stories/200707260858.html. Accessed 16 January 2014.
138. Anonymous. 2007. Counterfeit AIDS drugs plague Zimbabwe. The Real Truth, 21 September 2007. http://realtruth.org/news/070921-001-africa .html. Accessed 16 January 2014.
139. Anonymous. 2013. Counterfeit drugs flood Zim market. The Zimbabwe Independent, 25 October 2013. http://www.theindependent.co.zw/2013 /10/25/counterfeit-drugs-flood-zim-market/. Accessed 16 January 2014.
140. Pharmaceutical Security Institute. 2014. Media reports on pharmaceutical counterfeiting. http://www.psi-inc.org/index.cfm. Accessed 16 January 2014.
141. Appleby J. 2003. Fake drugs show up in US pharmacies. USA Today, 14 May 2003. http://www.usatoday.com/money/industries/health/drugs/2 003-05-14-fakedrug-cover_x.htm. Accessed 16 January 2014.
142. Apoola A, Sriskandabalan PS, Wade AA. 2001. Self-medication with zidovudine that was not. Lancet 357:1370. http://dx.doi.org/10.1016 /S0140-6736(00)04499-8.
143. The Partnership for Safe Medicines. 2008. Nigeria-bound HIV/AIDS drugs seized in Netherlands. http://www.safemedicines.org/nigeriabound-hivaids -drugs-seized-in-netherlands.html. Accessed 16 January 2014.
144. Anonymous. 2002. Counterfeit pharmaceuticals. First Global Forum on Pharmaceutical Anticounterfeiting, Geneva, Switzerland, 22 to 25 September 2002.
145. Chambuso MH, Ngassapa OD, Sayi JG, Jande MB, Mohamed Z. 2006. Quality of antiretroviral drugs, stavudine and indinavir capsules available in the Tanzanian market. Tanzania Med J 21:8-12. http://dx.doi.org /10.4314/tmj.v21i1.39202.
146. Nkengasong J. 2003. Counterfeit antiretroviral drugs. Medscape Infectious Diseases, 12 December 2003. http://www.medscape.com/viewarticle/46503 3. Accessed 16 January 2014.
147. Spake A. 2004. Fake drugs, real worries: high prices and the Internet are making U.S. patients easy prey. US News World Rep 137:46, 48, 50.
148. James JS. 2002. Counterfeit drugs: check combivir, serostim, epogen. AIDS Treat News 380:3-4.
149. Aoki N. 2002. Real fears over phony drugs: US health officials view spate of recent cases as evidence of rising trend. Boston Globe, 29 May 2002. http://www.bostonglobe.com/. Accessed 16 January 2014.
150. Anonymous. 2011. Kenya: government grapples with counterfeit ARVs. http://www.irinnews.org/report/94012/kenya-government-grapples -with-counterfeit-arvs. Accessed January 2014.
151. Broussard P. 1996. From Nigeria to Niger, strange vaccines against meningitis. Le Monde, 26 October 1996. http://www.lemonde.fr/. Accessed 16 January 2014.
152. Anonymous. 2005. Thirteen fake bird flu vaccine-makers punished. China View, 7 November 2005. http://news.xinhuanet.com/english/200 5-11/07/content_3745572.htm. Accessed 16 January 2014.
153. Anonymous. 2006. Charge filed in fake flu vaccine investigation. US Newswire. http://www.prnewswire.com/. Accessed 16 January 2014.
154. Hemachudha T, Mitrabhakdi E, Wilde H, Vejabhuti A, Siripataravanit S, Kingnate D. 1999. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis 28:143-144. http: //dx.doi.org/10.1086/517179.
155. Rasmussen CM, Thomas CW, Mulrooney RJ, Morrissey RA. 1973. Inadequate poliovirus immunity levels in immunized Illinois children. Am J Dis Child 126:465-469.
156. Onoja AL, Adu FD, Tomori O. 1992. Evaluation of measles vaccination programme conducted in two separate health centres. Vaccine 10:49-52. http://dx.doi.org/10.1016/0264-410X(92)90419-K.
157. Pribluda VS, Barojas A, Anez A, Lopez CG, Figueroa R, Herrera R, Nakao G, Nogueira FH, Pianetti GA, Povoa MM, Viana GM, Gomes MS, Escobar JP, Sierra OL, Norena SP, Veloz R, Bravo MS, Aldas MR, Hindssemple A, Collins M, Ceron N, Krishnalall K, Adhin M, Bretas G, Hernandez N, Mendoza M, Smine A, Chibwe K, Lukulay P, Evans L, III. 2012. Implementation of basic quality control tests for malaria medicines in Amazon Basin countries: results for the 2005-2010 period. Malar J 11:202. http://dx.doi.org/10.1186/1475-2875-11-202.
158. Tipke M, Diallo S, Coulibaly B, Storzinger D, Hoppe-Tichy T, Sie A, Muller O. 2008. Substandard anti-malarial drugs in Burkina Faso. Malar J 7:95. http://dx.doi.org/10.1186/1475-2875-7-95.
159. Newton PN, Fernandez FM, Plancon A, Mildenhall DC, Green MD, Ziyong L, Christophel EM, Phanouvong S, Howells S, McIntosh E, Laurin P, Blum N, Hampton CY, Faure K, Nyadong L, Soong CW, Santoso B, Zhiguang W, Newton J, Palmer K. 2008. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 5:e32. http://dx.doi.org/10.1371/journal .pmed.0050032.
160. Crampton T. 2003. Fake malaria pills haunt Asians. International Herald Tribune, 25 August 2003. http://www.iht.com/. Accessed 16 January 2014.
161. Bate R, Hess K. 2010. Anti-malarial drug quality in Lagos and Accra-a comparison of various quality assessments. Malar J 9:157. http://dx.doi .org/10.1186/1475-2875-9-157.
162. Bate R, Coticelli P, Tren R, Attaran A. 2008. Antimalarial drug quality in the most severely malarious parts of Africa-a six country study. PLoS One 3:e2132. http://dx.doi.org/10.1371/journal.pone.0002132.
163. Atemnkeng MA, De CK, Plaizier-Vercammen J. 2007. Quality control of active ingredients in artemisinin-derivative antimalarials within Ke- nya and DR Congo. Trop Med Int Health 12:68-74. http://dx.doi.org/10 .1111/j.1365-3156.2006.01769.x.
164. Odunfa O, Adegoke OA, Onaga IC. 2009. Pharmaceutical equivalence of some commercial samples of artesunate and amodiaquine tablets sold in southwestern Nigeria. Trop J Pharm Res 8:491-499.
165. Minzi OM, Moshi MJ, Hipolite D, Massele AY, Tomson G, Ericsson O, Gustafsson LL. 2003. Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. J Clin Pharm Ther 28:117-122. http://dx .doi.org/10.1046/j.1365-2710.2003.00470.x.
166. Alfadl AA, Abdoon S, Elamin M, Elnabi NG. 2006. Quality of antimalarial drugs in Sudan: results of post-marketing surveillance. Sudanese J Public Health 1:108-111.
167. Anonymous. 2001. Fake malaria drugs in Tanzania. The Pharmaletter, 20 February 2001. http://www.thepharmaletter.com/article/fake-malariadrugs -in-tanzania. Accessed 16 January 2014.
168. Wolff JC, Thomson LA, Eckers C. 2003. Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 17:215-221. http://dx.doi.org /10.1002/rcm.893.
169. Chryss J. 2004. Transcript of "File on 4": counterfeit drugs. Program number 04VY3040LHO. British Broadcasting Corporation, London, United Kingdom. http://news.bbc.co.uk/. Accessed 16 January 2014. (Transcript of radio program.)
170. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. 2005. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2:e100. http://dx.doi.org/10 .1371/journal.pmed.0020100.
171. Nigerian National Agency for Food and Drug Administration and Control. 2002. List of identified fake products (June 2002). NAFDAC reference 20-12. Nigerian National Agency for Food and Drug Administration and Control, Abuja, Nigeria. http://www.nafdac.gov.ng/. Accessed 16 January 2014.
172. Atemnkeng MA, Chimanuka B, Plaizier-Vercammen J. 2007. Quality evaluation of chloroquine, quinine, sulfadoxine-pyrimethamine and proguanil formulations sold on the market in East Congo DR. J Clin Pharm Ther 32:123-132. http://dx.doi.org/10.1111/j.1365-2710.2007 .00797.x.
173. World Health Organization. 1995. The quality of pharmaceutical drugs on the African walking. Analytical study in three countries: Cameroon, Madagascar, Chad. WHO/DAP/95.3. WHO, Geneva, Switzerland. http: //apps.who.int/medicinedocs/en/d/Js2212f/. Accessed 16 January 2014.
174. Abdi YA, Rimoy G, Ericsson O, Alm C, Massele AY. 1995. Quality of chloroquine preparations marketed in Dar es Salaam, Tanzania. Lancet 346:1161. http://dx.doi.org/10.1016/S0140-6736(95)91834-5.
175. Ogwal-Okeng JW, Okello DO, Odyek O. 1998. Quality of oral and parenteral chloroquine in Kampala. East Afr Med J 75:692-694.
176. Ogwal-Okeng JW, Owino E, Obua C. 2003. Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study. Afr Health Sci 3:2-6.
177. Abdo-Rabbo A, Bassili A, Atta H. 2005. The quality of antimalarials available in Yemen. Malar J 4:28. http://dx.doi.org/10.1186/1475-2875-4-28.
178. Anonymous. 2003. Counterfeiting abroad and home: British Pharmaceutical Conference 2003. J Pharm Pharmacol 55(Suppl):S1-S106.
179. Ashokraj Y, Kohli G, Kaul CL, Panchagnula R. 2005. Quality control of anti-tuberculosis FDC formulations in the global market. IIAccelerated stability studies. Int J Tuberc Lung Dis 9:1266-1272.
180. Boelaert M, Le Ray D, Van Der SP. 2002. How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis. Trop Med Int Health 7:955-959. http://dx.doi.org/10.1046/j.1365-3156 .2002.00959.x.
181. Cockburn R. 1982. Counterfeit drugs-the other killer in Lebanon. The Guardian, 10 December 1982. http://www.theguardian.com/uk-news. Accessed 16 January 2014.
182. Heath WJ. 2004. America's first drug regulation regime: the rise and fall of the Import Drug Act of 1848. Food Drug Law J 59:169-200.
183. Hebron Y, Tettey JN, Pournamdari M, Watson DG. 2005. The chemical and pharmaceutical equivalence of sulphadoxine/pyrimethamine tablets sold on the Tanzanian market. J Clin Pharm Ther 30:575-581. http://dx.doi.org/10.1111/j.1365-2710.2005.00687.x.
184. Sowunmi A, Salako LA, Ogunbona FA. 1994. Bioavailability of sulphate and dihydrochloride salts of quinine. Afr J Med Med Sci 23:275-278.
185. Sulaiman SM, Traore M, Engels D, Hagan P, Cioli D. 2001. Counterfeit praziquantel. Lancet 358:666-667. http://dx.doi.org/10.1016/S0140 -6736(01)05796-8.
186. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, Murray HW, Singh VP. 1998. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 59:139-143.
187. ten Ham M. 2003. Health risks of counterfeit pharmaceuticals. Drug Saf 26:991-997. http://dx.doi.org/10.2165/00002018-200326140-00001.
188. Agrawal S, Panchagnula R. 2004. In vitro evaluation of fixed dose combination tablets of anti-tuberculosis drugs after real time storage at ambient conditions. Pharmazie 59:782-785.
189. Ellard GA. 1999. The colorimetric analysis of anti-tuberculosis fixeddose combination tablets and capsules. Int J Tuberc Lung Dis 3:S343- S346.
190. Okeke IN, Lamikanra A, Edelman R. 1999. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 5:18-27. http://dx.doi.org/10.3201 /eid0501.990103.
191. Amon, JJ. 2008. Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Global Health 4:5. http://dx.doi.org/10.1186 /1744-8603-4-5.
192. Nsimba SE. 2008. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy. East Afr J Public Health 5:205-210.
193. Nsimba SE. 2009. Anti-retroviral (ARV) rationing schemes in developing countries: a review article on strategies and ethical issues related to the successes and failures of ARV programmes. East Afr J Public Health 6:219-222.
194. Anonymous. 2014. Risking your life: designer drugs and counterfeit medicines. http://www.kwikmed.org/risking-life-designer-drugs-counterfeit -medicines/. Accessed 16 January 2014.
195. World Health Organization. 2003. Counterfeit triple antiretroviral combination product (Ginovir 3D) detected in Cote d'Ivoire: Information Exchange System alert no 110. QSM/MC/IEA. WHO, Geneva, Switzerland. http://www.who.int/medicines/publications/drugalerts/Drug Alert110.pdf.
196. Newton PN, White NJ, Rozendaal JA, Green MD. 2002. Murder by fake drugs. BMJ 324:800-801. http://dx.doi.org/10.1136/bmj.324.7341.800.
197. Penzak SR, Acosta EP, Turner M, Tavel JA, Masur H. 2003. Analysis of generic nevirapine products in developing countries. JAMA 289:2648-2649. http://dx.doi.org/10.1001/jama.289.20.2648-c.
198. Houston S. 2002. Justice and HIV care in Africa-antiretrovirals in perspective. J Int Assoc Physicians AIDS Care 1:46-50. http://dx.doi.org/10 .1177/154510970200100202.
199. Hamers RL, Kityo C, Lange JM, de Wit TF, Mugyenyi P. 2012. Global threat from drug resistant HIV in sub-Saharan Africa. BMJ 344:e4159. http://dx.doi.org/10.1136/bmj.e4159.
200. Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, Herron W. 2000. Development of a high-performance liquid chromatographicmass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 745:373-388. http://dx.doi.org/10.1016/S0378-4347(00)00300-5.
201. U.S. Food and Drug Administration. 2005. Counterfeit drugs:questions and answers. http://www.fda.gov/drugs/drugsafety/ucm169898.htm. Accessed 16 January 2014.
202. Children's Vaccine Initiative. 1993. Working Group Meeting on Asia Initiative, 28 to 30 July 1993. Document CVI/MAC-5/93.12. Rockefeller Archives Center, New York, NY.
203. Banerjee A. 1995. Fake polio vaccine kills 11 children in Nadia. The Asian Age, 5 April 1995. http://www.asianage.com/. Accessed 16 January 2014.
204. Pakharenko-Anderson A. 2002. Building legislation and regulatory implementation environments: the Ukraine experience. First Global Forum on Pharmaceutical Anticounterfeiting, Geneva, Switzerland, 22 to 25 September 2002.
205. Ogunshe AA, Adepoju AA, Oladimeji ME. 2011. Clinical efficacy and health implications of inconsistency in different production batches of antimycotic drugs in a developing country. J Pharm Bioallied Sci 3:158-164. http://dx.doi.org/10.4103/0975-7406.76501.
206. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217. http://dx.doi.org/10.1038/nature03342.
207. Surendran A. 2004. World agencies try to stem flood of fake drugs. Nat Med 10:111. http://dx.doi.org/10.1038/nm0204-111a.
208. Koch E, Simmm M, Wech M. 1994. Mafia fake drugs. Courrier International 204:36. http://www.courrierinternational.com/. Accessed 16 January 2014.
209. van Wyk JA, Malan FS, van Rensburg LJ, Oberem PT, Allan MJ. 1997. Quality control in generic anthelmintics: is it adequate? Vet Parasitol 72:157-165. http://dx.doi.org/10.1016/S0304-4017(97)00022-8.
210. Anonymous. 1997. Quality control and essential drugs. Lancet 350:601. http://dx.doi.org/10.1016/S0140-6736(97)21035-4.
211. Pandya SK. 1988. Letter from Bombay. An unmitigated tragedy. BMJ 297:117-119.
212. Okuonghae HO, Ighogboja IS, Lawson JO, Nwana EJ. 1992. Diethylene glycol poisoning in Nigerian children. Ann Trop Paediatr. 12:235-238.
213. Alter K, Fernandez F, Green M, Newton P. 2004. Analysis of counterfeit antimalarial drugs. Eur Pharm Rev 3:1-5.
214. Fernandez FM, Cody RB, Green MD, Hampton CY, McGready R, Sengaloundeth S, White NJ, Newton PN. 2006. Characterization of solid counterfeit drug samples by desorption electrospray ionization and direct-analysis-in-real-time coupled to time-of-flight mass spectrometry. Chem Med Chem. 1:702-705. http://dx.doi.org/10.1002/cmdc.2006 00041.
215. Issack MI. 2001. Substandard drugs. Lancet 358:1463. http://dx.doi.org /10.1016/S0140-6736(01)06516-3.
216. Alubo SO. 1994. Death for sale: a study of drug poisoning and deaths in Nigeria. Soc Sci Med 38:97-103. http://dx.doi.org/10.1016/0277-9536 (94)90304-2.
217. Ringwald P, Same EA, Keundjian A, Kedy MD, Basco LK. 2000. Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. 1. Surveillance of in vitro and in vivo resistance of Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon. Trop Med Int Health 5:612-619.
218. Ringwald P, Bickii J, Basco L. 1996. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 347:24-28. http://dx.doi.org/10.1016/S0140-6736(96)91558-5.
219. White NJ. 1999. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41:301-308.
220. Wernsdorfer WH. 1994. Epidemiology of drug resistance in malaria. Acta Trop 56:143-156. http://dx.doi.org/10.1016/0001-706X(94)90060-4.
221. Laing R, Vrakking H, Fourie B. 2004. Quality and stability of TB medicines: let the buyer beware! Int J Tuberc Lung Dis 8:1043-1044.
222. Terlouw DJ, Nahlen BL, Courval JM, Kariuki SK, Rosenberg OS, Oloo AJ, Kolczak MS, Hawley WA, Lal AA, Kuile FO. 2003. Sulfadoxinepyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. Antimicrob Agents Chemother 47:2929-2932. http://dx.doi.org/10.1128/AAC.47.9.2929-2932.2003.
223. Barnes KI, Watkins WM, White NJ. 2008. Antimalarial dosing regimens and drug resistance. Trends Parasitol 24:127-134. http://dx.doi.org /10.1016/j.pt.2007.11.008.
224. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. http://whqlibdoc.who.int/publications/2010/97892415479 25_eng.pdf. Accessed 25 January 2014.
225. Basco LK, Ringwald P, Manene AB, Chandenier J. 1997. False chloroquine resistance in Africa. Lancet 350:224. http://dx.doi.org/10.1016 /S0140-6736(05)62397-5.
226. Saywell T, McManus J. 2002. What's in that pill? Far East Economic Review, 21 February 2002, p 34-40.
227. Anonymous. 2004. Protecting consumers from counterfeit drugs. FDA Consum 38:12-13.
228. Burns W. 2006.WHOlaunches taskforce to fight counterfeit drugs. Bull World Health Organ 084: 689-690. http://dx.doi.org/10.1590/S0042 -96862006000900005.
229. World Health Organization. 2014. Combating counterfeit drugs: a concept paper for effective international collaboration. http://www.who.int /medicines/services/counterfeit/CombatingCounterfeitDrugs_Concept paper.pdf. Accessed 16 January 2014.
230. Council of Europe. 2014. Counterfeiting of medical products (MEDICRIME). http://www.coe.int/t/dghl/standardsetting/medicrime/default _EN.asp/. Accessed 24 January 2014.
231. Interpol. 2014. Pharmaceutical crime. COM/FS/2012-01/DCO-04. http: //www.interpol.int/. Accessed 24 January 2014.
232. World Customs Organization. 2009. International operation combats the online supply of counterfeit and illegal medicines. http://www.wcoo md.org/en/media/newsroom/2009/november/international-operationcombats- the-online-supply-of-counterfeit-and-illegal-medicines.aspx. Accessed 24 January 2014.
233. United Nations Office on Drugs and Crime. 2012. World Customs Organization make a dent in counterfeit goods and drug shipments. htt p://www.unodc.org/unodc/en/press/releases/2012/June/un-drugs-andcrime- office-world-customs-organization-make-a-dent-on-counterfeit -goods-and-drug-shipments.html. Accessed 24 January 2014.
234. World Health Organization. 2012. New global mechanism to combat substandard/spurious/falselylabelled/falsified/counterfeit medical products. http://www.who.int/medicines/news/TRA-SE_EMP.pdf. Accessed 24 January 2014.
235. Wertheimer AI, Norris J. 2009. Safeguarding against substandard/ counterfeit drugs: mitigating a macroeconomic pandemic. Res Social Adm Pharm 5:4-16. http://dx.doi.org/10.1016/j.sapharm.2008.05.002.